National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Cabozantinib (Cabometyx®) in combination with nivolumab (Opdivo®) for 1L RCC. HTA ID: 22018

Cabozantinib (Cabometyx®), in combination with nivolumab (Opdivo®), is indicated for the first-line treatment of advanced renal cell carcinoma in adults.

 

NCPE Assessment Process Complete
Rapid review commissioned 28/03/2022
Rapid review completed 11/05/2022
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of cabozantinib (Cabometyx®) in combination with nivolumab compared with the current standard of care, on the basis of the proposed price relative to currently available therapies.